| Literature DB >> 32822771 |
Gary Gintant1, Emily Pfeiffer Kaushik2, Tromondae Feaster3, Sonja Stoelzle-Feix4, Yasunari Kanda5, Tomoharu Osada6, Godfrey Smith7, Katherine Czysz8, Ralf Kettenhofen9, Hua Rong Lu10, Beibei Cai11, Hong Shi12, Todd Joseph Herron13, Qianyu Dang14, Francis Burton15, Li Pang16, Martin Traebert17, Yama Abassi18, Jennifer Beck Pierson19, Ksenia Blinova20.
Abstract
Human stem cell-derived cardiomyocytes (hSC-CMs) hold great promise as in vitro models to study the electrophysiological effects of novel drug candidates on human ventricular repolarization. Two recent large validation studies have demonstrated the ability of hSC-CMs to detect drug-induced delayed repolarization and "cellrhythmias" (interrupted repolarization or irregular spontaneous beating of myocytes) linked to Torsade-de-Pointes proarrhythmic risk. These (and other) studies have also revealed variability of electrophysiological responses attributable to differences in experimental approaches and experimenter, protocols, technology platforms used, and pharmacologic sensitivity of different human-derived models. Thus, when evaluating drug-induced repolarization effects, there is a need to consider 1) the advantages and disadvantages of different approaches, 2) the need for robust functional characterization of hSC-CM preparations to define "fit for purpose" applications, and 3) adopting standardized best practices to guide future studies with evolving hSC-CM preparations. Examples provided and suggested best practices are instructional in defining consistent, reproducible, and interpretable "fit for purpose" hSC-CM-based applications. Implementation of best practices should enhance the clinical translation of hSC-CM-based cell and tissue preparations in drug safety evaluations and support their growing role in regulatory filings.Entities:
Keywords: Cardiotoxicity; Cardiovascular safety assessment; Cellrhythmias; CiPA; Delayed repolarization; JiCSA; Nonclinical safety; Proarrhythmic risk assessment; Safety pharmacology; hSC-CM
Mesh:
Substances:
Year: 2020 PMID: 32822771 DOI: 10.1016/j.yrtph.2020.104756
Source DB: PubMed Journal: Regul Toxicol Pharmacol ISSN: 0273-2300 Impact factor: 3.271